The Leader in Quality Life Science Training

The Evolution of Combination Products: Key Takeaways from Dr. Michael Drues

March 3, 2025

Combination products (groundbreaking innovations that combine drugs, devices, or biologics) are reshaping healthcare. Yet, their development and regulation present challenges. 


Dr. Michael Drues, biomedical engineer and regulatory expert, offers critical insights into these complexities through his CfPIE course, Introduction to Medical Combination Products. Dr. Drues specializes in regulatory strategy, product development, and connecting engineering with clinical needs.


Keep reading to learn about combination products, the challenges they face, and strategies for streamlining the regulatory process.

The Importance of Effective Document Management

Understanding Combination Products

Combination products integrate two or more regulated components, such as a drug-eluting stent (device + drug) or a prefilled syringe (biologic + device). These products offer enhanced therapeutic benefits but require careful regulatory navigation.


Market Growth & Trends

Improvements in drug delivery, materials, and personalized medicine drive the growth of combination products. As demand rises, companies find new ways to improve treatments while meeting regulatory requirements.


Regulatory Complexity

Combination products differ from traditional drugs or devices because they must follow multiple rules. Understanding which laws apply and how they work together is key to achieving regulatory approval and succeeding in the market.


Common Challenges in the Regulatory Pathway

Bringing a combination product to market isn’t as straightforward as a standalone drug, device, or biologic. Below are some common challenges:


Multiple Regulatory Pathways

Determining the primary jurisdiction for a combination product can be difficult. The FDA assigns oversight to one of its centers based on the product's primary mode of action. These include CDER (the Center for Drug Evaluation and Research), CDRH (the Center for Devices and Radiological Health), and CBER (the Center for Biologics Evaluation and Research). However, some products blur these lines, leading to complex submission requirements.


Labeling & Classification

Correct classification and labeling affect how regulators review a product. Misclassifying or mislabeling a product can cause delays and extra challenges. 


Post-Approval Monitoring

Combination products require ongoing monitoring to track safety, effectiveness, and adverse events. Companies must have systems in place to manage post-market requirements and regulatory reporting.


Key Takeaways from Dr. Michael Drues’ CfPIE Course

Dr. Michael Drues’ CFPIE course helps simplify the complex regulatory process for combination products by covering:


Proactive Regulatory Strategy

Waiting until later stages to address compliance can result in costly setbacks. Dr. Drues’ approach encourages companies to anticipate potential issues, engage with regulators early, and integrate regulatory strategy into product development.


Bridging Engineering and Clinical Insight

Successful combination products require collaboration between engineers, clinicians, and regulatory teams. Dr. Drues advocates for a cross-functional approach, ensuring that technical feasibility aligns with clinical needs. This teamwork helps companies create innovative products that work well in real-world settings.


Communication with Regulators

Working with the FDA and other agencies requires more than just submitting paperwork. Dr. Drues teaches how to communicate effectively, helping companies set expectations, avoid confusion, and speed up approvals.


Impact on Product Development 

A strong regulatory strategy helps with approval and shapes the entire product development process, including:


Time to Market

Regulatory delays can seriously affect a product’s launch date. A well-structured regulatory strategy helps avoid obstacles and speeds up time-to-market while ensuring safety and compliance.


Risk Management

A structured risk management approach helps identify potential issues early, from technical failures to regulatory noncompliance. Dr. Drues’ teachings align with the five steps of risk management: identifying, assessing, mitigating, implementing, and monitoring risks to enhance product success.


Long-Term Success

Regulatory landscapes evolve, and ongoing compliance ensures continued market viability. Companies integrating regulatory foresight into their culture better position themselves for long-term innovation and growth. 


Regulatory Success Starts with the Right Approach

Dr. Michael Drues offers essential insights into mastering combination products. His proactive strategy, focus on teamwork, and emphasis on effective communication with regulators give companies the edge they need for success.


Sign up for Dr. Michael Drues’ CfPIE course today!



paper_plane

Need more information on our life-science training course?

Get In Touch With Us Today!

Contact Us

Blog Categories

By The Center for Professional Innovation and Education March 3, 2025
Streamline development with effective CMC strategies. Learn how process optimization, risk management, and collaboration drive quality and faster approvals.
By The Center for Professional Innovation and Education March 3, 2025
Discover how Good Laboratory Practice (GLP) guidelines ensure data integrity and regulatory compliance. Explore benefits and CfPIE training for trusted results.
Share by: